Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02350712 | Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer | completed | Phase 1 | 15 | Daiichi SankyoINDUSTRY | 1 | Sep 11, 2018 | clinicaltrials |
| NCT01422603 | Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) | completed | Phase 1 / Phase 2 | 9 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT02317016 | Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer | completed | Phase 1 | 44 | AstraZenecaINDUSTRY | 4 | Jul 31, 2018 | clinicaltrials |
| NCT01458067 | A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 3 | Jul 24, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01585701 | Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | completed | Phase 1 | 56 | Cancer Research UKOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01800071 | A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma | completed | Phase 1 | 22 | Cancer Research UKOTHER | 1 | Jul 17, 2018 | clinicaltrials |
| NCT00445198 | A Phase 1/2a Study of ABT-263 in Subjects With Small Cell Lung Cancer (SCLC) or Other Non-Hematological Malignancies | completed | Phase 1 / Phase 2 | 86 | AbbVie (prior sponsor, Abbott)INDUSTRY | 3 | Jun 6, 2018 | clinicaltrials |
| NCT02022761 | Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma | completed | Phase 1 | 32 | Biota Scientific Management Pty LtdINDUSTRY | 1 | May 30, 2018 | clinicaltrials |
| NCT01195480 | CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL)(CD19TPALL) | terminated | Phase 1 / Phase 2 | 29 | University College, LondonOTHER | 2 | May 17, 2018 | clinicaltrials |
| NCT02690350 | An Open Study Assessing the Safety and Tolerability of U3-1784 | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 16, 2018 | clinicaltrials |
| NCT03315091 | Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours | completed | Phase 1 | 31 | AstraZenecaINDUSTRY | 3 | Apr 30, 2018 | clinicaltrials |
| NCT01653912 | Dose-finding Study in Platinum-Resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 59 | AccentureINDUSTRY | 3 | Apr 2, 2018 | clinicaltrials |
| NCT01397825 | MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine | completed | Phase 1 / Phase 2 | 45 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | Mar 27, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT01809210 | Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer(SELECT-3) | completed | Phase 1 | 55 | AstraZenecaINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT02280993 | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients | unknown | Phase 1 | 72 | Marjolein SpieringOTHER | 4 | Mar 13, 2018 | clinicaltrials |
| NCT00299494 | Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL) | completed | Phase 1 / Phase 2 | 119 | PfizerINDUSTRY | 13 | Mar 8, 2018 | clinicaltrials |
| NCT02439346 | Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel | terminated | Phase 1 | 15 | BayerINDUSTRY | 2 | Mar 7, 2018 | clinicaltrials |
| NCT02004106 | A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 110 | Hoffmann-La RocheINDUSTRY | 8 | Mar 6, 2018 | clinicaltrials |
| NCT01767623 | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants | completed | Phase 1 | 8 | Hoffmann-La RocheINDUSTRY | 7 | Feb 13, 2018 | clinicaltrials |
| NCT00139620 | A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function | completed | Phase 1 | 39 | OSI PharmaceuticalsINDUSTRY | 2 | Feb 8, 2018 | clinicaltrials |
| NCT01090466 | Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium | completed | Phase 1 / Phase 2 | 15 | Cardiff UniversityOTHER | 1 | Feb 6, 2018 | clinicaltrials |
| NCT01390571 | Olaparib and Temozolomide in Treating Patients With Relapsed Glioblastoma | completed | Phase 1 | 34 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01668550 | A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours(AZD0424) | terminated | Phase 1 | 43 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01805375 | A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies | completed | Phase 1 | 28 | Cancer Research UKOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01237678 | A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 181 | ImmunoGen, Inc.INDUSTRY | 4 | Jan 18, 2018 | clinicaltrials |
| NCT01573156 | Vascular Targeted Photodynamic Therapy T1a Renal Tumours(KCM201) | terminated | Phase 1 / Phase 2 | 5 | University of OxfordOTHER | 1 | Jan 10, 2018 | clinicaltrials |
| NCT00387387 | Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 2 | Nov 17, 2017 | clinicaltrials |
| NCT00528281 | A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | completed | Phase 1 | 18 | GlaxoSmithKlineINDUSTRY | 4 | Nov 17, 2017 | clinicaltrials |
| NCT00678977 | A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors | completed | Phase 1 | 22 | GlaxoSmithKlineINDUSTRY | 2 | Nov 14, 2017 | clinicaltrials |
| NCT01954043 | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | completed | Phase 1 | 23 | GlaxoSmithKlineINDUSTRY | 3 | Nov 14, 2017 | clinicaltrials |
| NCT00866528 | Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Nov 13, 2017 | clinicaltrials |
| NCT00903422 | Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS) | completed | Phase 1 | 98 | GlaxoSmithKlineINDUSTRY | 11 | Nov 13, 2017 | clinicaltrials |
| NCT00992121 | An Open-Label Pharmacodynamic Study of Bevacivumab and Pazopanib in Renal Cell Carcinoma | completed | Phase 1 | 11 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01290354 | Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer | completed | Phase 1 | 10 | GlaxoSmithKlineINDUSTRY | 1 | Nov 13, 2017 | clinicaltrials |
| NCT01738451 | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | completed | Phase 1 | 50 | GlaxoSmithKlineINDUSTRY | 3 | Nov 13, 2017 | clinicaltrials |
| NCT00972881 | Capecitabine, Irinotecan Hydrochloride, Cetuximab, and Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer(EXCITE) | completed | Phase 1 / Phase 2 | 82 | University College, LondonOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT01449058 | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | completed | Phase 1 | 139 | Array BioPharmaINDUSTRY | 7 | Oct 2, 2017 | clinicaltrials |
| NCT02100007 | ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 46 | MEI Pharma, Inc.INDUSTRY | 2 | Oct 2, 2017 | clinicaltrials |
| NCT00136578 | Ispinesib In Combination With Carboplatin In Patients With Solid Tumors | completed | Phase 1 | 30 | GlaxoSmithKlineINDUSTRY | 2 | Sep 25, 2017 | clinicaltrials |
| NCT01399840 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | completed | Phase 1 | 33 | PfizerINDUSTRY | 2 | Sep 15, 2017 | clinicaltrials |
| NCT02521389 | Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143 | completed | Phase 1 | 35 | MEI Pharma, Inc.INDUSTRY | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01851265 | D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 3 | Aug 28, 2017 | clinicaltrials |
| NCT03191981 | Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma(MUKfourteen) | withdrawn | Phase 1 / Phase 2 | 0 | University of LeedsOTHER | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01138410 | Study of a DNA Immunotherapy to Treat Melanoma | terminated | Phase 1 / Phase 2 | 35 | Scancell LtdINDUSTRY | 1 | Aug 21, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials